6 drug(s) with this reaction
17,987 total reports
Therapeutic Product Effect Incomplete has been reported as an adverse reaction across 6 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 17,987 adverse event reports mention therapeutic product effect incomplete in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with therapeutic product effect incomplete, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have therapeutic product effect incomplete listed in their FDA adverse event reports, sorted by report count:
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
6 drug(s) manufactured by Abbvie Inc have therapeutic product effect incomplete listed in their FDA adverse event reports: Humira, ADALIMUMAB, RISANKIZUMAB-RZAA, UPADACITINIB, VENETOCLAX, and others.
There are a combined 17,987 reports of therapeutic product effect incomplete across 6 Abbvie Inc drug(s) in the FDA adverse event database.